FDA Updates

This section provides a brief overview of new cancer drugs and new indications approved by the FDA between December 9, 2022, and February 3, 2023.

This section provides a brief overview of new cancer drugs and new indications approved by the FDA between October 21, 2022, and December 1, 2022.

This section provides a brief overview of new cancer drugs and new indications approved by the FDA between August 24, 2022, and September 30, 2022.

This section provides a brief overview of new indications for cancer drugs approved by the FDA between June 22, 2022, and August 11, 2022.

This section provides a brief overview of new cancer drugs and new indications approved by the FDA between April 1, 2022, and May 27, 2022.

This section provides a brief overview of new cancer drugs and new indications approved by the FDA between February 28 and March 31, 2022.

This section provides a brief overview of new cancer drugs and new fast-track designations approved by the FDA between January 10, 2022, and January 25, 2022.

This section provides a brief overview of new cancer drugs and indications approved by the FDA between November 29, 2021, and December 15, 2021.

This section provides a brief overview of new cancer drugs and indications approved by the FDA between August 13, 2021, and September 22, 2021.

On September 20, 2021, the FDA announced the availability of its revised final guidance for industry on biosimilar development and the Biologics Price Competition and Innovation Act of 2009 (BPCI Act).